Review of Peptide Growth Factors in Benign Prostatic Hyperplasia and Urological Malignancy

The Journal of Urology

Volumn 153, Issue 4, 1995, Pages 1085-1096

  Steiner, Mitchell S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

CELL COMMUNICATION; CELL INTERACTION; GROWTH REGULATION; HORMONAL CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; URINARY TRACT CANCER;

ANIMAL; BLADDER NEOPLASMS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; GROWTH SUBSTANCES; HUMAN; KIDNEY NEOPLASMS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SOMATOMEDINS; TRANSFORMING GROWTH FACTOR BETA; UROGENITAL NEOPLASMS;

EID: 0028950552     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)67516-5     Document Type: Review

References (139)

1. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
2. The transforming growth factor-beta family
3. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity
4. Epidermal growth factor
5. Transforming growth factor-alpha. A model for membrane-anchored growth factors
6. Epidermal growth factor
7. Expression of the transforming growth factor-alpha gene in tumor cells and normal tissue
8. The heparin-binding (fibroblast) growth factor family of proteins
9. Fibroblast growth factor and its involvement in developmental processes
10. Human basic fibroblast growth factor: nucleotide sequence and genomic organization
11. Structural characterization and biological functions of fibroblast growth factor
12. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken choriollantoic membrane
13. Keratinocyte growth factor (KGF) modifies the response of prostatic epithelial cells to stimulatory and inhibitory factors
14. Growth factors and cancer
15. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines
16. Insulin-like growth factors (IGFs) IGF receptors and IGF-binding proteins in primary cultures of prostate epithelial cells
17. Stimulation of bone matrix apposition in vitro by local growth factors: a comparison between insulin-like growth factor I, platelet-derived growth factor, and transforming growth factor beta
18. Transforming growth factor-beta stimulates production of insulin-like growth factor-binding protein-3 by human skin fibroblasts
19. Potential role of HBGF (FGF) and TGF-beta on prostate growth, Adv
20. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development
21. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights
22. Transforming growth factor-beta and its actions on cellular growth and differentiation
23. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium
24. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance
25. Modulation of the immune response by transforming growth factor beta
26. Role of peptide growth factors in the prostate: a review
27. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog
28. Inhibition of IGF-II-stimulated growth of prostate cancer cells by IGF-I receptor-specific monoclonal antibody and antisense oligonucleotide of IGF-II messenger RNA
29. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues
30. Prostatic epidermal growth factor receptors and their regulation by androgens
31. Androgenic regulation of epidermal growth factor in the mouse ventral prostate
32. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study
33. Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate
34. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines
35. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy
36. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP)
37. Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell
38. Transforming growth factor-alpha and its receptor are expressed in the epithelium of the rat prostate gland
39. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev
40. Heparin-binding growth factor isolated from human prostatic extracts
41. Characterization of growth factors derived from the rat ventral prostate
42. Evidence for an organ- and sex-specific role of basic fibroblast growth factor in the development of the fetal mammalian reproductive tract
43. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor
44. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia
45. A form of basic fibroblast growth factor is secreted into the adluminal fluid of the rat coagulating gland
46. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors
47. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma
48. Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family
49. A keratinocyte growth factor receptor-derived peptide antagonist identifies part of the ligand binding site
50. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture
51. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors
52. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization
53. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro
54. Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma
55. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death
56. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro
57. Isolation of a prostate carcinoma cell proliferation-inhibiting factor from human seminal plasma and its similarity to transforming growth factor beta
58. Normal and abnormal development of the male urogenital tract: role of androgens, mesenchymal-epithelial interactions, and growth factors
59. Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture
60. The partial dependency of human prostatic growth factor on steroid hormones in stimulating thymidine incorporation into DNA
61. Gene activity during the early phase of androgen-stimulated rat prostate regrowth
62. The prostate gland: morphology and pathology
63. The int-2 gene product acts as an epithelial growth factor in transgenic mice
64. The mouse int-2 gene exhibits basic fibroblast growth factor activity in a basic fibroblast growth factor-responsive cell line
65. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model
66. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth
67. Characterization of the receptor for keratinocyte growth factor. Evidence for multiple fibroblast growth factor receptors
68. Influence of transforming growth factor beta 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts
69. Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line
70. Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma
71. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor
72. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha
73. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues
74. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
75. Basic fibroblast growth factor fused to a signal peptide transforms cells
76. Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA
77. Basic fibroblast growth factor in human prostate cancer cells
78. Localization of basic fibroblast growth factor (bFGF) in a metastatic cell line (AT-3) established from the Dunning prostatic carcinoma of rat: application of a specific monoclonal antibody
79. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells
80. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors
81. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1
82. Activation of androgen receptor mediated transcription by insulin-like growth factor-1 in prostatic tumour cell lines
83. Transforming growth factor beta 1 as a biomarker for prostate cancer
84. Expression of transforming growths (TGF-alpha and TGF-beta) and epidermal growth factor (EGF) in normal and malignant rat prostate
85. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression
86. Mutation of the retinoblastoma suseptibility protein correlates with resistance to TGF beta inhibition in prostate cancer
87. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study
88. Modulation of transforming growth factor beta 1 action growth factors and extracellular matrix
89. Potential role of T-lymphocytes in prostate tumor growth enhancement by transforming growth factor beta1 (TGF beta 1)
90. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix
91. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential
92. Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells
93. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer
94. Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer
95. Inhibitory effects of the bone-derived growth factors osteoinductive factor and transforming growth factor-beta on isolated osteoclasts
96. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur
97. Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein, DVR-6 (bone morphogenetic protein-6)
98. Expression of bone morphogenetic protein-6 (BMP-6) in normal rat prostate and in the Dunning rat prostate adenocarcinoma model
99. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine
100. Transforming growth factor type beta in normal human urine
101. Epidermal growth factor in the normal and neoplastic kidney and bladder
102. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors
103. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
104. Loss of KGF receptor expression in aggressive transitional cell carcinoma (TCC) of the bladder
105. The epidermal growth factor receptor and the prognosis of bladder cancer
106. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells
107. Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line
108. Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential
109. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
110. Loss of TGF-beta 1 induced exfoliation, repression of c-myc and cytostasis in vitro in bladder tumor cells from carcinogen-treated F344 rats
111. Growth factors in urologic tissues: detection, characterization, and clinical applications
112. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue
113. Origin of urinary epidermal growth factor in humans: excretion of endogenous EGF and infused [sup 131 I]-human EGF and kidney histochemistry
114. Growth factors and kidney development
115. Epidermal growth factor receptor gene analysis in renal cell carcinoma
116. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma
117. Metanephric transforming growth factor-beta 1 regulates nephrogenesis in vitro
118. Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues
119. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas
120. Transforming growth factor-beta modulates the parathyroid hormone-related protein-induced responses in renal epithelial cells
121. Transforming growth factor-beta is a renin secretagogue at picomolar concentrations
122. A study of growth factors in human renal cysts with or without renal cell carcinoma
123. Expression of differentiation antigens and growth-related genes in normal kidney autosomal dominant polycystic kidney disease and renal cell carcinoma
124. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha
125. Detection of tumor angiogenesis factor in adenocarcinoma of the kidney
126. Analysis of papillary adenocarcinoma
127. Influence of growth factors on in vitro invasiveness and type IV collagenolysis of human renal cell carcinoma cells
128. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases
129. Differential expression of mRNAs transforming growth factor beta 1 and beta 3 and c-fos in human normal prostate, benign prostatic hyperplasia and prostatic cancer
130. Quantitative determination of transforming growth factor-beta in serum and urine of patients with bladder cancer and its expression in malignant and non-malignant primary epithelial cells
131. Alpha-interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon
132. Evidence for an equilibrium intermediate in the folding-unfolding pathway of a transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein
133. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstain, produced by MH435-hF3
134. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
135. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action
136. Suramin, an active drug for prostate cancer: interim observations in a phase I trial
137. Recombinant human EGF (rhEGF) enhances the sensitivity of a broad spectrum of human cancer cells to cisplatin
138. Therapeutic manipulation of cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine
139. Growth factor deprivation therapy utilizing antisense oligonucleotides in the treatment of PC-3 and LNCaP tumors growing in athymic nude mice